Collecting data on patients with plasmablastic lymphoma
An International Multicenter Observational Retrospective Study on Plasmablastic Lymphoma Patients
This study is collecting information from patients with plasmablastic lymphoma to better understand their treatment, outcomes, and the disease itself.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Fondazione Italiana Linfomi - ETS Academic / other |
| Locations | 23 sites (Aviano, PN and 22 other locations) |
| Trial ID | NCT06781359 on ClinicalTrials.gov |
What this trial studies
This observational, multicenter, international study aims to gather comprehensive data on clinical and pathological characteristics, treatment regimens, outcomes, and prognostic factors in patients diagnosed with plasmablastic lymphoma (PBL). The study will retrospectively analyze medical records and histopathological samples from patients diagnosed between January 1, 2000, and December 31, 2022. A centralized review of pathological samples will be conducted to ensure accurate diagnosis and to establish a recommended immunohistochemical diagnostic panel for PBL. Additionally, exploratory analyses will be performed to enhance the understanding of PBL.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with a histologically confirmed diagnosis of plasmablastic lymphoma and complete medical records.
Not a fit: Patients with any histology other than plasmablastic lymphoma or those lacking complete medical records will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the diagnosis and treatment strategies for patients with plasmablastic lymphoma.
How similar studies have performed: While there have been studies on lymphoma, this specific focus on plasmablastic lymphoma is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022 * Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report * Age \> 18 years old * Availability of complete medical records * Availability of histopathological material requested by the study Exclusion Criteria: * Any other histology than PBL * Lack of complete medical records * Lack of histopathological material requested by the study
Where this trial is running
Aviano, PN and 22 other locations
- IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati — Aviano, Pn, Italy (Recruiting)
- Ospedale C.e G. Mazzoni, U.O.C. di Ematologia — Ascoli Piceno, Italy (Recruiting)
- ASST Spedali Civili di Brescia, Ematologia — Brescia, Italy (Not_yet_recruiting)
- A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo — Cuneo, Italy (Recruiting)
- Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia — Florence, Italy (Recruiting)
- ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia — Milan, Italy (Not_yet_recruiting)
- ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia — Milan, Italy (Recruiting)
- Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia — Milan, Italy (Recruiting)
- Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia — Milan, Italy (Not_yet_recruiting)
- Fondazione IRCCS San Gerardo dei Tintori, Ematologia — Monza, Italy (Recruiting)
- AOU Maggiore della Caritа di Novara, SCDU Ematologia — Novara, Italy (Recruiting)
- Azienda Ospedaliera Universitaria di Padova, Ematologia — Padova, Italy (Not_yet_recruiting)
- Presidio ospedaliero A. Tortora, U.O. Onco-ematologia — Pagani, Italy (Not_yet_recruiting)
- Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia — Reggio Emilia, Italy (Recruiting)
- Azienda Ospedaliera Universitaria Sant' Andrea, Ematologia — Roma, Italy (Recruiting)
- Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione — Roma, Italy (Recruiting)
- Universitа Cattolica S. Cuore, Ematologia — Roma, Italy (Not_yet_recruiting)
- Azienda Ospedaliero Universitaria Senese, U.O.C. Ematologia — Siena, Italy (Not_yet_recruiting)
- A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria — Torino, Italy (Not_yet_recruiting)
- A.O.U. Città della Salute e della Scienza di Torino, S.C. Ematologia — Torino, Italy (Not_yet_recruiting)
- Ospedale S. Chiara, S.S. di Ematologia — Trento, Italy (Recruiting)
- ULSS2 Marca Trevigiana, Ospedale Ca' Foncello, S.C di Ematologia — Treviso, Italy (Not_yet_recruiting)
- ULSS 8 Berica - Ospedale S. Bortolo, Ematologia — Vicenza, Italy (Recruiting)
Study contacts
- Principal investigator: Alessia Castellino, MD — UO Ematologia, AO Santa Croce e Carle, Cuneo - Italy
- Study coordinator: Uffici Studi FIL
- Email: startup@filinf.it
- Phone: +390131033153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.